FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, David A. Eichenbaum, MD, discusses the design of phase 3 trials of sozinibercept for the treatment of neovascular age-related macular degeneration.
Eichenbaum said there have been a number of anti-VEGF-A molecules that have demonstrated improvements in durability, but there have not been as many that have shown improvement in visual acuity. Phase 2 research showed promise for sozinibercept in this area.
“We’re very excited to test sozinibercept in large, phase 3 programs of about 990 patients each with the goal of reproducing those results and showing that we can improve visual acuity, hopefully, by up to five letters or more,” he said.
Sources/Disclosures
Collapse
Eichenbaum D. Rationale for the design of the phase 3 superiority clinical trials of sozinibercept combination therapy targeting inhibition of VEGF-C/-D and VEGF-A for neovascular age-related macular degeneration. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Disclosures:
Eichenbaum reports being an investigator and consultant for Genentech, Opthea and Regeneron, being a speaker for Genentech and Regeneron and being an investigator and speaker for Bayer.